# A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults

> **NCT05972993** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 114 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** mRNA-CR-04 vaccine 10μg
- **BIOLOGICAL:** mRNA-CR-04 vaccine 30μg
- **BIOLOGICAL:** mRNA-CR-04 vaccine 100μg
- **DRUG:** Placebo
- **BIOLOGICAL:** mRNA-CR-04 vaccine 3μg

## Key facts

- **NCT ID:** NCT05972993
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-07
- **Primary completion:** 2024-05-09
- **Final completion:** 2024-10-14
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05972993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05972993, "A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05972993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*